FDA warns PureRawz its tianeptine products are unapproved new drugs sold with drug claims.
What happened
In August 2025, FDA reviewed purerawz.co and the company’s Facebook and Instagram accounts and found tianeptine products offered for sale in the U.S. Despite “laboratory and research use only” labeling, FDA says product pages, social media posts, and testimonials showed the products were intended for human use to treat depression, anxiety, and other conditions. FDA says there are no approved applications for these products, making them unapproved new drugs.
What FDA found
The company sold tianeptine products as drugs for human use even though they were labeled for laboratory or research use only.
FD&C Act §201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128The tianeptine products are new drugs without an FDA-approved application, so selling them violates the law.
FD&C Act §505(a) and §301(d), 21 U.S.C. 355(a) and 331(d)The products are not generally recognized as safe and effective for the uses described in their labeling.
FD&C Act §201(p), 21 U.S.C. 321(p)
What FDA wants
Notify FDA in writing within 15 working days of receipt of the specific steps taken to correct the violations and prevent recurrence, with related documentation; if correction is not complete, explain the delay and when it will be finished. Send the response to CDER/OC/Office of Unapproved Drugs and Labeling Compliance at FDAADVISORY@fda.hhs.gov with the firm name and identifier 715218 in the subject line.
Who should pay attention
- online sellers of research chemicals
- brands and retailers selling tianeptine
- quality teams reviewing drug claims on websites and social media
This is a summary. Read the original letter on fda.gov.